After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

PORTLAND, IA, UNITED STATES, January 28, 2025 /EINPresswire / -- According to the report, the global biosimilars <a target=_blank href= ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit ... the response rates in the two Tepezza trials were (PDF) 71% and 83%. Cross-trial comparisons can be misleading ...

Report with market evolution powered by AI - The global mobile application market size is estimated to grow by USD 2.63 ...

If you have participated in the Amgen Scholars Program in a previous year at one of ... Before applying please prepare all required documents as PDF files (max 10mb per file): Your CV. Please be sure ...

Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amgen's market standing. Stay informed and make well-considered decisions with our ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...